CFAK-C4
/ CureFAKtor
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 19, 2011
CureFAKtor Pharmaceuticals to present at 10th Annual BIO Investor Forum
(PRNewswire)
- CureFAKtor received Orphan Drug Designation by the U.S. FDA for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer and planning a Phase I clinical study in 2012
Anticipated P1 trial • Orphan drug • Oncology
1 to 1
Of
1
Go to page
1